

SYNGENTA AG
Form 6-K
May 28, 2013

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of May 2013

Commission File Number: 001-15152

SYNGENTA AG
(Translation of registrant's name into English)

Schwarzwaldallee 215
4058 Basel
Switzerland
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form ☒ 20-F	Form ☐ 40-F
---	------------------------------------

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐	No ☒
------------------------------	--

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐	No ☒
------------------------------	--

Indicate by check mark whether by furnishing the information contained in this Form, the Registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes ☐	No ☒
------------------------------	--

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

Re: SYNGENTA AG
Disclosure: “Syngenta launches breakthrough seed treatment nematicide”

Herewith we furnish a press release related to Syngenta AG. The full text of the press release is the following:
#

Syngenta International AG

Media Office

CH-4002 Basel
Switzerland

Tel: +41 61 323 2323

Fax: +41 61 323 2424

www.syngenta.com

Media contacts:

Paul Barrett

Switzerland +41 61 323 2323

Paul
Minehart

USA + 1 202 737 8913

Analyst/Investor contacts:

Jennifer
Gough

Switzerland +41 61 323 5059

USA +1 202 737 6521

Lars

Oestergaard

Switzerland +41 61 323 6793

USA +1 202 737 6520

Basel, Switzerland May 27, 2013

Syngenta launches breakthrough seed treatment nematicide

- Novel innovation against damaging nematodes
- First commercial product from Pasteuria Bioscience acquisition
- Initial launch in USA for use on soybeans; further registrations pending

Syngenta announced today the launch of CLARIVA™, a proprietary seed treatment nematicide based on the Pasteuria technology acquired in 2012.

CLARIVA consists of naturally occurring soil bacteria with a unique, direct mode of action on nematodes: microscopic worm-shaped soil organisms, which cause significant damage to all major agricultural crops.

Syngenta Chief Operating Officer, John Atkin, said: "Soybean growers in particular have long been searching for additional tools to manage the widespread cyst nematode problem, which in the USA alone causes more than a billion dollars of annual yield losses. CLARIVA will take nematode control to a new level and reinforce our global leadership in seed treatment innovation."

Multi-year field trial data demonstrate that CLARIVA delivers immediate and long-lasting protection of plant root systems resulting in significant yield benefits.

CLARIVA will be available in the USA for the 2014 growing season. It will be combined with other leading Syngenta seed care compounds as a complete solution for soybeans. Further registrations across major crops worldwide are planned.

Syngenta is one of the world's leading companies with more than 27,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com

Syngenta – May 27, 2013 / Page 1 of 2

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Syngenta – May 27, 2013 / Page 2 of 2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SYNGENTA AG

Date: May 27, 2013

By: /s/ Tobias Meili
Name: Tobias Meili
Title: Head Corporate Legal Affairs

By: /s/ Daniel Michaelis
Name: Daniel Michaelis
Title: Senior Legal Counsel
